MIRA INFORM REPORT
|
Report No. : |
324571 |
|
Report Date : |
11.06.2015 |
IDENTIFICATION DETAILS
|
Name : |
SPIRO LIFECARE PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
Cabin No.1, B-208/209, Classique Centre, Off Mahakali Caves Road, Andheri
(East), Mumbai – 400093, Maharashtra |
|
Tel. No.: |
91-22-66276077 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
31.03.2015 (Provisional) |
|
|
|
|
Date of
Incorporation : |
14.02.2014 |
|
|
|
|
Com. Reg. No.: |
11-253280 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs. 0.100
Million |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24100MH2014PTC253280 |
|
|
|
|
IEC No.: |
0314028846 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
MUMS80003A |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAUCS3007J |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer and Trader of Pharmaceutical Products. |
|
|
|
|
No. of Employees
: |
24 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
NB |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
NB |
New Business |
|
|
Status : |
New Company |
|
|
|
|
Payment Behaviour : |
Slow but correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a new company incorporated during 14th February
2014, and it is establishing itself gradually. Mr. Pankaj Vyas, CFO has provided information to us and claimed that
company has started its trading activities from January 2015 and
manufacturing activities of company is expected to start from 22nd
October 2015. As per provisional financial record of 2015, company has achieved
revenue of Rs. 35.300 Million in its first year of business operations and
achieved profit of Rs. 0.200 Million during a year under a review. However it
has taken huge external borrowing which led to leverage balance profile of
the company. Trade relations are improving. Payments are reported to be slow but
correct. In view of recent establishment backed by limited history of business
operations, the company can be considered for business dealings on safe and
secured trade terms and conditions.
|
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2015
|
Country Name |
Previous Rating (31.12.2014) |
Current Rating (31.03.2015) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EXTERNAL AGENCY RATING
NOT AVAILABLE
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2013.
INFORMATION PARTED BY
|
Name : |
Mrs. Bhavna Siddhpura |
|
Designation : |
Senior Finance Manager |
|
Contact No.: |
91-9870132012 |
|
Date : |
09.06.2015 |
LOCATIONS
|
Registered Office : |
Cabin No.1, B-208/209, Classique Centre, Off Mahakali Caves Road,
Andheri (East), Mumbai – 400093, Maharashtra, India |
|
Tel. No.: |
91-22-66276077/ 66277777 |
|
Mobile No.: |
91-9870132012 [Mrs. Bhavna Siddhpura] |
|
Fax No.: |
91-22-42116040/ 42656040 |
|
E-Mail : |
|
|
Website : |
|
|
Area : |
1990 Sq. ft. |
|
Location : |
Rented |
|
|
|
|
Factory : |
Plot No. 268, 270 and 271, GIDC, Umbergaon – 396171,
Gujarat, India |
|
Area : |
71554 Sq. ft. |
|
Location : |
Rented |
DIRECTORS
AS ON 30.09.2014
|
Name : |
Mr. Hitesh Parmanand Asrani |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
4 Golden View, Sunder Nagar, Kalina, Santacruz (East), Mumbai –
400029, Maharashtra, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
24.10.1970 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Qualification : |
MBA |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Experience : |
20 Years |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
14.02.2014 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PAN No.: |
AARPA2893C |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
00561701 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Vinod Anant Dali |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
A-602, Kusum Bharati CHS, Dattapada Road, Rajendra Nagar, Borivali (East),
Mumbai – 400066, Maharashtra, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
04.06.1968 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Qualification : |
Bachelors Degree in Pharmacy |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Experience : |
20 Years |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
14.02.2014 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PAN No.: |
AEQPD5626R |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
05005219 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Pankaj Rameshchandra Vyas |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Additional director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
407-B, Satyam CHSL, New Link Road, Opposite M.H.B. Post Office, Borivali (West), Mumbai – 400091, Maharashtra, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
47 Years |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Qualification : |
CA |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Experience : |
20 Years |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
15.12.2014 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PAN No.: |
ADGPV4521L |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
02496291 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Sanjeev Anant Gupte |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Additional director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
Sumer Castle, E-401, 4th Floor, L.B.S. Marg, Thane (West), Mumbai – 400601, Maharashtra, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
51 Years |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Qualification : |
B. Sc. And MBA |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Experience : |
20 Years |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
15.12.2014 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PAN No.: |
AHTPC1880C |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
03042650 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Name : |
Mr. Rajesh Shripad Ghangurde |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Designation : |
Additional director |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Address : |
106, Kamla Terrace, Subhash Road, Parle (East), Mumbai – 400057, Maharashtra, India |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Birth/Age : |
44 Years |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Qualification : |
MBA |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Experience : |
20 Years |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Date of Appointment : |
15.12.2014 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
PAN No.: |
AADPG2743H |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIN No.: |
05005218 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Directorship :
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
KEY EXECUTIVES
|
Name : |
Mrs. Bhavna Siddhpura |
|
Designation : |
Senior Finance Manager |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 30.09.2014
|
Names of Shareholders |
No. of Shares |
Percentage of Holding |
|
Hitesh Parmanand Asrani |
2250 |
22.50 |
|
Rajesh Shripad Ghangurde |
2250 |
22.50 |
|
Vinod Anant Dali |
2250 |
22.50 |
|
Sanjeev Anant Gupte |
2250 |
22.50 |
|
Pankaj Rameshchandra Vyas |
1000 |
10.00 |
|
|
|
|
|
Total |
10000 |
100.00 |
AS ON 30.09.2014
|
Equity Share Breakup |
Percentage of Holding |
|
Category |
|
|
Directors
or relatives of directors |
100.00 |
|
|
|
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer and Trader of Pharmaceutical Products. |
|
|
|
|
Brand Names : |
-- |
|
|
|
|
Agencies Held : |
-- |
|
|
|
|
Exports : |
|
|
Products : |
-- |
|
Countries : |
-- |
|
|
|
|
Imports : |
|
|
Products : |
-- |
|
Countries : |
-- |
|
|
|
|
Terms : |
|
|
Selling : |
Cash [60 Days] |
|
|
|
|
Purchasing : |
Cash [30 Days] |
PRODUCTION STATUS: NOT AVAILABLE
GENERAL INFORMATION
|
Suppliers : |
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Customers : |
Wholesalers
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
No. of Employees : |
24 (Approximately) |
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Bankers : |
|
||||||||||||||||||||||
|
|
|
||||||||||||||||||||||
|
Facilities : |
-- |
|
|
|
|
Auditors 1 : |
|
|
Name : |
Chheda Vyas and Associates Chartered Accountants |
|
Address : |
C-32, Gautam Nagar, L.T. Road, Near Shri Sagar Hotel, Borivali (West),
Mumbai –
400092, Maharashtra, India |
|
Tel. No.: |
91-22-28996574/ 28334408 |
|
E-Mail : |
|
|
Income-tax
PAN of auditor or auditor's firm : |
AABFC2409A |
|
|
|
|
Auditors 2 : |
|
|
Name : |
B M Parekh and Company Chartered Accountants |
|
Address : |
3/203, Navjivan Society, Lamington Road, Mumbai – 400008, Maharashtra,
India |
|
Tel. No.: |
91-22-23073126 |
|
Fax No.: |
91-22-23088804 |
|
E-Mail : |
|
|
|
|
|
Memberships : |
-- |
|
|
|
|
Collaborators : |
-- |
|
|
|
|
Associates/Subsidiaries : |
Not Available |
CAPITAL STRUCTURE
AS ON 31.03.2014
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
100,000 |
Equity Shares |
Rs. 10/- each |
Rs. 1.000 Million |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
10,000 |
Equity Shares |
Rs. 10/- each |
Rs. 0.100
Million |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Million]
ABRIDGED
BALANCE SHEET
|
SOURCES OF FUNDS |
|
31.03.2015 [Provisional] |
31.03.2014 |
|
I.
EQUITY AND LIABILITIES |
|
|
|
|
(1)Shareholders' Funds |
|
|
|
|
(a) Share Capital |
|
0.100 |
0.100 |
|
(b) Reserves & Surplus |
|
0.493 |
(0.015) |
|
(c) Money received against share warrants |
|
0.000 |
0.000 |
|
|
|
|
|
|
(2) Share
Application money pending allotment |
|
0.000 |
0.000 |
|
Total
Shareholders’ Funds (1) + (2) |
|
0.593 |
0.085 |
|
|
|
|
|
|
(3)
Non-Current Liabilities |
|
|
|
|
(a) Long-term borrowings |
|
8.672 |
0.000 |
|
(b) Deferred tax liabilities (Net) |
|
0.000 |
0.000 |
|
(c)
Other long term liabilities |
|
0.000 |
0.000 |
|
(d)
long-term provisions |
|
0.000 |
0.000 |
|
Total
Non-current Liabilities (3) |
|
8.672 |
0.000 |
|
|
|
|
|
|
(4) Current Liabilities |
|
|
|
|
(a)
Short term borrowings |
|
0.000 |
0.015 |
|
(b)
Trade payables |
|
9.724 |
0.000 |
|
(c)
Other current liabilities |
|
1.229 |
0.021 |
|
(d)
Short-term provisions |
|
0.215 |
0.000 |
|
Total
Current Liabilities (4) |
|
11.168 |
0.036 |
|
|
|
|
|
|
TOTAL |
|
20.433 |
0.121 |
|
|
|
|
|
|
II.
ASSETS |
|
|
|
|
(1) Non-current assets |
|
|
|
|
(a)
Fixed Assets |
|
|
|
|
(i)
Tangible assets |
|
0.184 |
0.000 |
|
(ii)
Intangible Assets |
|
0.000 |
0.000 |
|
(iii)
Capital work-in-progress |
|
0.000 |
0.000 |
|
(iv) Intangible assets under development |
|
0.000 |
0.000 |
|
(b) Non-current
Investments |
|
0.000 |
0.000 |
|
(c) Deferred tax assets
(net) |
|
0.000 |
0.000 |
|
(d) Long-term Loan
and Advances |
|
0.000 |
0.000 |
|
(e)
Other Non-current assets |
|
0.027 |
0.037 |
|
Total
Non-Current Assets |
|
0.211 |
0.037 |
|
|
|
|
|
|
(2) Current assets |
|
|
|
|
(a)
Current investments |
|
0.000 |
0.000 |
|
(b)
Inventories |
|
0.000 |
0.000 |
|
(c)
Trade receivables |
|
16.205 |
0.000 |
|
(d)
Cash and cash equivalents |
|
0.541 |
0.084 |
|
(e)
Short-term loans and advances |
|
3.476 |
0.000 |
|
(f)
Other current assets |
|
0.000 |
0.000 |
|
Total
Current Assets |
|
20.222 |
0.084 |
|
|
|
|
|
|
TOTAL |
|
20.433 |
0.121 |
PROFIT
& LOSS ACCOUNT
|
|
PARTICULARS |
|
31.03.2015 [Provisional] |
31.03.2014 |
|
|
|
SALES |
|
|
|
|
|
|
|
Revenue from Operations |
|
35.325 |
0.000 |
|
|
|
Other Income |
|
0.000 |
0.000 |
|
|
|
TOTAL (A) |
|
35.325 |
0.000 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Purchases |
|
24.755 |
0.000 |
|
|
|
Employees benefits expense |
|
5.748 |
0.000 |
|
|
|
Operating and Other expenses |
|
4.034 |
0.015 |
|
|
|
TOTAL (B) |
|
34.537 |
0.015 |
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
|
0.788 |
(0.015) |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
|
0.012 |
0.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
|
0.776 |
(0.015) |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
|
0.052 |
0.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
|
0.724 |
(0.015) |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
|
0.215 |
0.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
|
0.509 |
(0.015) |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
|
50.90 |
(1.50) |
|
CURRENT MATURITIES
OF LONG TERM DEBT DETAILS
|
Particulars |
|
31.03.2015 [Provisional] |
31.03.2014 |
|
Current Maturities of Long term debt |
|
NA |
NA |
|
|
|
|
|
|
Cash generated from operations |
|
NA |
NA |
KEY
RATIOS
|
PARTICULARS |
|
|
31.03.2015 [Provisional] |
31.03.2014 |
|
Net Profit Margin (PAT / Sales) |
(%) |
|
1.44 |
0.00 |
|
|
|
|
|
|
|
Operating Profit Margin (PBDIT/Sales) |
(%) |
|
2.23 |
0.00 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
|
3.54 |
(12.40) |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
|
1.22 |
(0.18) |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
|
14.62 |
0.18 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
|
1.81 |
2.33 |
Total Liability = Short-term Debt + Long-term Debt + Current Maturities
of Long-term debts
FINANCIAL ANALYSIS
[all figures are
in Rupees Million]
DEBT EQUITY RATIO
|
Particulars |
31.03.2014 |
31.03.2015
[Provisional] |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
|
Share Capital |
0.100 |
0.100 |
|
Reserves & Surplus |
-0.015 |
0.493 |
|
Money received against share warrants |
0.000 |
0.000 |
|
Share Application money pending allotment |
0.000 |
0.000 |
|
Net
worth |
0.085 |
0.593 |
|
|
|
|
|
Long-term borrowings |
0.000 |
8.672 |
|
Short term borrowings |
0.015 |
0.000 |
|
Total
borrowings |
0.015 |
8.672 |
|
Debt/Equity ratio |
0.176 |
14.624 |
YEAR-ON-YEAR GROWTH
|
Year on Year Growth |
31.03.2014 |
31.03.2015
[Provisional] |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
|
Sales |
0.000 |
35.325 |
|
|
|
|
NET PROFIT MARGIN
|
Net Profit Margin |
31.03.2014 |
31.03.2015
[Provisional] |
|
|
(Rs.
In Million) |
(Rs.
In Million) |
|
Sales |
0.000 |
35.325 |
|
Profit/ (Loss) |
(0.015) |
0.509 |
|
|
|
1.44% |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check list by
info agents |
Available in
Report (Yes/No) |
|
1 |
Year of establishment |
Yes |
|
2 |
Constitution of the entity -Incorporation
details |
Yes |
|
3 |
Locality of the entity |
Yes |
|
4 |
Premises details |
Yes |
|
5 |
Buyer visit details |
-- |
|
6 |
Contact numbers |
Yes |
|
7 |
Name of the person contacted |
Yes |
|
8 |
Designation of contact person |
Yes |
|
9 |
Promoter’s background |
Yes |
|
10 |
Date of Birth of Proprietor / Partners /
Directors |
Yes |
|
11 |
Pan Card No. of Proprietor / Partners |
Yes |
|
12 |
Voter Id Card No. of Proprietor / Partners |
No |
|
13 |
Type of business |
Yes |
|
14 |
Line of Business |
Yes |
|
15 |
Export/import details (if applicable) |
No |
|
16 |
No. of employees |
Yes |
|
17 |
Details of sister concerns |
No |
|
18 |
Major suppliers |
No |
|
19 |
Major customers |
No |
|
20 |
Banking Details |
Yes |
|
21 |
Banking facility details |
Yes |
|
22 |
Conduct of the banking account |
Yes |
|
23 |
Financials, if provided |
Yes |
|
24 |
Capital in the business |
Yes |
|
25 |
Last accounts filed at ROC, if applicable |
Yes |
|
26 |
Turnover of firm for last three years |
Yes |
|
27 |
Reasons for variation <> 20% |
-- |
|
28 |
Estimation for coming financial year |
Yes |
|
29 |
Profitability for last three years |
Yes |
|
30 |
Major shareholders, if available |
Yes |
|
31 |
External Agency Rating, if available |
No |
|
32 |
Litigations that the firm/promoter involved
in |
-- |
|
33 |
Market information |
-- |
|
34 |
Payments terms |
Yes |
|
35 |
Negative Reporting by Auditors in the
Annual Report |
No |
------------------------------------------------------------------------------------------------------------------------------
UNSECURED LOANS
(RS.
IN MILLION)
|
PARTICULARS |
31.03.2015 |
|
LONG-TERM BORROWINGS |
|
|
Directors, Members and Relatives |
8.672 |
|
|
|
|
Total |
8.672 |
------------------------------------------------------------------------------------------------------------------------------
COMPUTATION OF TOTAL INCOME
(RS.
IN MILLION)
|
PARTICULARS |
31.03.2014 |
|
|
|
|
|
|
INCOME FROM PROFIT/ GAINS OF BUSINESS/ PROFESSION |
|
|
|
|
|
|
|
Income from Business/ Profession
|
|
|
|
Spiro Lifecare Private Limited |
(0.015) |
|
|
|
-------------- |
|
|
Net Profit / (Loss) |
(0.015) |
|
|
|
|
|
|
Loss carried forward |
(0.015) |
|
|
|
-------------- |
|
|
|
|
0.000 |
|
|
|
-------------- |
|
Gross Total Income |
|
0.000 |
|
|
|
|
|
Total Income |
|
0.000 |
|
|
|
-------------- |
|
Tax on Total Income |
|
0.000 |
|
|
|
-------------- |
|
Tax Payable |
|
0.000 |
|
|
|
-------------- |
|
Net Tax + Interest Payable |
|
0.000 |
------------------------------------------------------------------------------------------------------------------------------
DSCR RATIO
(RS.
IN MILLION)
|
PARTICULARS |
2016 |
2017 |
2018 |
2019 |
2020 |
|
|
|
|
|
|
|
|
Profit After Tax |
2.110 |
11.353 |
24.109 |
36.771 |
49.455 |
|
|
|
|
|
|
|
|
Depreciation |
21.038 |
38.330 |
31.659 |
26.221 |
21.765 |
|
|
|
|
|
|
|
|
Interest on Term Loan |
15.297 |
22.126 |
18.984 |
15.706 |
12.429 |
|
|
|
|
|
|
|
|
TOTAL 1 ( A + B +
C ) |
38.444 |
71.809 |
74.752 |
78.698 |
83.648 |
|
|
|
|
|
|
|
|
Interest on Term Loan |
15.297 |
22.126 |
18.984 |
15.706 |
12.429 |
|
|
|
|
|
|
|
|
Repayment of TL Instalment |
0.000 |
18.911 |
25.214 |
25.214 |
25.214 |
|
|
|
|
|
|
|
|
TOTAL 2 ( C + D ) |
15.297 |
41.036 |
44.199 |
40.921 |
37.643 |
|
|
|
|
|
|
|
|
D.S.C.R. (Total 1
/ Total2) |
2.51 |
1.75 |
1.69 |
1.92 |
2.22 |
|
|
|
|
|
|
|
|
Average DSCR |
2.47 |
||||
------------------------------------------------------------------------------------------------------------------------------
PROJECTED BALANCE SHEET
(RS.
IN MILLION)
|
PARTICULARS |
2015-2016 |
2016-2017 |
2017-2018 |
2018-2019 |
2019-2020 |
|
SOURCES OF FUNDS |
|
|
|
|
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
|
Paid-up share capital |
50.000 |
50.000 |
50.000 |
50.000 |
50.000 |
|
Fund From Relatives |
50.000 |
50.000 |
50.000 |
50.000 |
50.000 |
|
Reserve and Surplus |
2.110 |
13.463 |
37.572 |
58.843 |
93.298 |
|
|
|
|
|
|
|
|
LOAN FUNDS |
|
|
|
|
|
|
Cash Credit |
50.000 |
60.000 |
70.000 |
80.000 |
90.000 |
|
Term Loan |
176.500 |
157.589 |
132.375 |
107.161 |
81.946 |
|
Unsecured Loan |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
Total |
328.610 |
331.052 |
339.947 |
333.004 |
337.244 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
Fixed Assets |
|
|
|
|
|
|
Gross Block |
0.182 |
249.712 |
249.712 |
249.712 |
249.712 |
|
Addition |
249.531 |
-- |
-- |
-- |
-- |
|
Less : Acc. Depreciation |
21.089 |
59.420 |
91.078 |
117.299 |
139.064 |
|
Net Block |
228.623 |
190.293 |
158.634 |
132.413 |
110.648 |
|
Licence purchase |
20.000 |
20.000 |
20.000 |
20.000 |
20.000 |
|
|
|
|
|
|
|
|
Deposits |
-- |
-- |
-- |
-- |
-- |
|
Advances to suppliers |
7.412 |
2.204 |
2.424 |
2.666 |
2.933 |
|
Investments |
-- |
-- |
2.500 |
4.500 |
7.500 |
|
Loans & Advances |
1.500 |
1.500 |
1.500 |
1.500 |
3.000 |
|
|
|
|
|
|
|
|
Current Assets |
|
|
|
|
|
|
Sundry Debtors |
51.954 |
96.311 |
135.231 |
149.278 |
165.066 |
|
Cash and bank balance |
2.492 |
2.531 |
4.450 |
3.538 |
3.366 |
|
Stock |
29.848 |
74.918 |
84.044 |
94.232 |
105.477 |
|
Other Current Assets |
4.439 |
4.883 |
6.348 |
6.665 |
6.998 |
|
|
|
|
|
|
|
|
Total - A |
88.733 |
178.642 |
230.073 |
253.713 |
280.906 |
|
|
|
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
|
Sundry Creditors |
12.518 |
32.649 |
31.658 |
32.863 |
35.631 |
|
Tax Provisions |
3.578 |
6.958 |
14.936 |
19.998 |
22.504 |
|
Other Provisions |
1.562 |
3.069 |
3.375 |
3.713 |
4.394 |
|
Advances from Customers |
-- |
-- |
-- |
-- |
-- |
|
Instalment of Term Loan (Due within one
Year) |
-- |
18.911 |
25.214 |
25.214 |
25.214 |
|
|
|
|
|
|
|
|
Total - B |
17.659 |
61.587 |
75.184 |
81.789 |
87.744 |
|
|
|
|
|
|
|
|
Net Current Assets (A-B) |
71.074 |
117.056 |
154.889 |
171.924 |
193.163 |
|
|
|
|
|
|
|
|
Total |
328.610 |
331.052 |
339.947 |
333.004 |
337.244 |
------------------------------------------------------------------------------------------------------------------------------
PROJECTED PROFIT & LOSS ACCOUNT
(RS.
IN MILLION)
|
PARTICULARS |
2015-2016 |
2016-2017 |
2017-2018 |
2018-2019 |
2019-2020 |
|
|
|
|
|
|
|
|
Sales |
210.704 |
561.942 |
618.537 |
680.815 |
749.665 |
|
|
|
|
|
|
|
|
Growth % |
-- |
267 |
110 |
110 |
110 |
|
|
|
|
|
|
|
|
Less : Cost of Goods sold |
152.920 |
431.611 |
472.343 |
511.336 |
554.205 |
|
|
|
|
|
|
|
|
Less : Freight/ Insurance/ Distb |
4.588 |
12.948 |
14.170 |
15.340 |
16.626 |
|
|
|
|
|
|
|
|
Gross Profit |
53.197 |
117.383 |
132.024 |
154.139 |
178.834 |
|
|
|
|
|
|
|
|
Gross Profit % |
25.25 |
20.89 |
21.34 |
22.64 |
23.86 |
|
|
|
|
|
|
|
|
Less : Salary |
3.500 |
9.600 |
11.520 |
13.800 |
15.456 |
|
|
|
|
|
|
|
|
Other cost |
4.425 |
18.216 |
21.715 |
31.242 |
42.771 |
|
|
|
|
|
|
|
|
NPBIDT |
45.272 |
89.567 |
98.789 |
109.097 |
120.607 |
|
|
|
|
|
|
|
|
NPBIDT % |
21.49 |
15.94 |
15.97 |
16.02 |
16.09 |
|
|
|
|
|
|
|
|
Product Registion W/off |
-- |
-- |
-- |
-- |
-- |
|
|
|
|
|
|
|
|
Depreciation |
21.038 |
38.330 |
31.659 |
26.221 |
21.765 |
|
|
|
|
|
|
|
|
NPBIT |
24.234 |
51.237 |
67.130 |
82.876 |
98.843 |
|
|
|
|
|
|
|
|
NPBIT % |
11.50 |
9.12 |
10.85 |
12.17 |
13.18 |
|
|
|
|
|
|
|
|
Interest |
18.547 |
29.926 |
28.084 |
26.106 |
24.129 |
|
|
|
|
|
|
|
|
NPBT |
5.688 |
21.311 |
39.046 |
56.769 |
74.714 |
|
|
|
|
|
|
|
|
NPBT % |
2.70 |
3.79 |
6.31 |
8.34 |
9.97 |
|
|
|
|
|
|
|
|
Tax Provision |
3.578 |
9.958 |
14.936 |
19.998 |
25.259 |
|
|
|
|
|
|
|
|
PAT |
2.110 |
11.353 |
24.109 |
36.771 |
49.455 |
|
|
|
|
|
|
|
|
PAT % |
1.00 |
2.02 |
3.90 |
5.40 |
6.60 |
------------------------------------------------------------------------------------------------------------------------------
ASSESSMENT OF WORKING CAPITAL REQUIREMENTS
OPERATING STATEMENT
(RS. IN MILLION)
|
PARTICULARS |
31.03.2016 5 Months |
31.03.2017 |
31.03.2018 |
31.03.2019 |
31.03.2020 |
|
|
|
|
|
|
|
|
1.
Gross Sales |
|
|
|
|
|
|
i)
Domestic Sales |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
ii) Export Sales |
210.704 |
561.942 |
618.537 |
680.815 |
749.665 |
|
|
|
|
|
|
|
|
TOTAL SALES |
210.704 |
561.942 |
618.537 |
680.815 |
749.665 |
|
|
|
|
|
|
|
|
2.
Less Excise/ Custom duty |
-- |
-- |
-- |
-- |
-- |
|
|
|
|
|
|
|
|
3. NET SALES |
210.704 |
561.942 |
618.537 |
680.815 |
749.665 |
|
|
|
|
|
|
|
|
4.
% age rise or fall in net sales as compared to previous year |
0.00 |
10.01 |
10.07 |
10.07 |
10.11 |
|
|
|
|
|
|
|
|
5. COST OF SALES |
|
|
|
|
|
|
i) Raw materials (including stores &
other items used in the process of manufacture |
|
|
|
|
|
|
a. Imported |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Indigenous |
182.768 |
476.680 |
481.470 |
521.523 |
565.449 |
|
|
|
|
|
|
|
|
SUB
- TOTAL |
182.768 |
476.680 |
481.470 |
521.523 |
565.449 |
|
|
|
|
|
|
|
|
ii) Other spares |
|
|
|
|
|
|
a. Imported |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Indigenous |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
SUB
- TOTAL |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
iii) Direct Expenses |
4.588 |
12.948 |
14.170 |
15.340 |
16.626 |
|
|
|
|
|
|
|
|
iv) Wages and Labour Charges |
3.500 |
9.600 |
11.520 |
13.800 |
15.456 |
|
|
|
|
|
|
|
|
v) Other Expenses |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
vi) Depreciation |
21.038 |
38.330 |
31.659 |
26.221 |
21.765 |
|
|
|
|
|
|
|
|
SUB
- TOTAL |
211.893 |
537.559 |
538.819 |
576.885 |
619.296 |
|
|
|
|
|
|
|
|
Add:
Opening stocks in process |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
Less:
Closing stocks in process |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
COST
OF PRODUCTION |
211.893 |
537.559 |
538.819 |
576.885 |
619.296 |
|
|
|
|
|
|
|
|
Add:
Opening stocks of Finished Goods |
0.000 |
29.848 |
74.918 |
84.044 |
94.232 |
|
|
|
|
|
|
|
|
Less:
Closing stocks of Finished Goods |
29.848 |
74.918 |
84.044 |
94.232 |
105.477 |
|
|
|
|
|
|
|
|
TOTAL COST OF SALES |
182.045 |
492.490 |
529.692 |
566.697 |
608.051 |
|
|
|
|
|
|
|
|
6.
Selling, General and Administrative Expenses |
4.425 |
18.216 |
21.715 |
31.242 |
42.771 |
|
|
|
|
|
|
|
|
7.
SUB TOTAL (5+6) |
186.470 |
510.706 |
551.408 |
597.939 |
650.822 |
|
|
|
|
|
|
|
|
8.
Operating Profit before Interest |
24.234 |
51.237 |
67.130 |
82.876 |
98.843 |
|
|
|
|
|
|
|
|
9.
Interest |
18.547 |
29.926 |
28.084 |
26.106 |
24.129 |
|
a) Interest on Cash Credit |
3.250 |
7.800 |
9.100 |
10.400 |
11.700 |
|
b) Interest on Term Loan |
15.297 |
22.126 |
18.984 |
15.706 |
12.429 |
|
|
|
|
|
|
|
|
10.
Operating Profit after Interest |
5.688 |
21.311 |
39.046 |
56.769 |
74.714 |
|
|
|
|
|
|
|
|
11.
i) Add other non operating income |
|
|
|
|
|
|
a. Deferred Income Tax |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Other Misc. Income |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
SUB
TOTAL (Income) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
ii) Deduct other non-operating expenses |
|
|
|
|
|
|
a. Prior year expenses |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Others |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
SUB
TOTAL (Expenses) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
Net
of other non operating income/expenses |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
12.
Profit before Tax/Loss |
5.688 |
21.311 |
39.046 |
56.769 |
74.714 |
|
|
|
|
|
|
|
|
13.
Provision for taxes |
3.578 |
9.958 |
14.936 |
19.998 |
25.259 |
|
|
|
|
|
|
|
|
14. Net Profit/Loss |
2.110 |
11.353 |
24.109 |
36.771 |
49.455 |
|
|
|
|
|
|
|
|
15.
a. Equity dividend paid |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Dividend rate |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
16. Retained Profit |
2.110 |
11.353 |
24.109 |
36.771 |
49.455 |
|
|
|
|
|
|
|
|
17.
Retained Profit/Net Profit (%) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
------------------------------------------------------------------------------------------------------------------------------
ANALYSIS OF BALANCE SHEET
(RS. IN MILLION)
|
PARTICULARS |
31.03.2016 5 Months |
31.03.2017 |
31.03.2018 |
31.03.2019 |
31.03.2020 |
|
|
|
|
|
|
|
|
LIABILITIES |
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
|
|
|
|
|
Long
term borrowings from banks (inclg. BP/BD and the excess borrowings placed on
repayment basis but exclude bills drawn under LCs) |
|
|
|
|
|
|
i)
From applicant bank- CC |
50.000 |
60.000 |
70.000 |
80.000 |
90.000 |
|
ii)
From Existing Bank - OD |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
SUB
TOTAL (A) |
50.000 |
60.000 |
70.000 |
80.000 |
90.000 |
|
|
|
|
|
|
|
|
2.
Short term borrowings from others /ICDs taken |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
3.
Sundry creditors |
12.518 |
32.649 |
31.658 |
32.863 |
35.631 |
|
|
|
|
|
|
|
|
4.
Advances payments from customers,
deposits from dealers |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
5.
Provision for taxes |
3.578 |
6.958 |
14.936 |
19.998 |
22.504 |
|
|
|
|
|
|
|
|
6.
Bonus Payable |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
7.
Other statutory liabilities (due within one year) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
8.
Deposits/ Instalments of term loans/ DPGs/ debentures etc (due within one
year) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
9.
Other current liabilities and provisions (due within one year) specify major
items |
|
|
|
|
|
|
a. Other liabilities and Provision |
1.562 |
3.069 |
3.375 |
3.713 |
4.394 |
|
b. |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
c. |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
SUB
TOTAL (B) |
17.659 |
61.587 |
75.184 |
81.789 |
87.744 |
|
|
|
|
|
|
|
|
10. TOTAL CURRENT LIABILITIES |
67.659 |
121.587 |
145.184 |
161.789 |
177.744 |
|
|
|
|
|
|
|
|
TERM LIABILITIES |
|
|
|
|
|
|
11.
Debentures (not maturing within one year) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
12.
Security Deposit on Lease of Land |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
13.
Term loans (exclusive of instalments payable within one year) |
176.500 |
157.589 |
132.375 |
107.161 |
81.946 |
|
|
|
|
|
|
|
|
14.
Housing loans (exclusive of instalments payable within one year) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
15 Unsecured loans |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
16.
Loans from Others |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
17. TOTAL TERM LIABILITIES |
176.500 |
157.589 |
132.375 |
107.161 |
81.946 |
|
|
|
|
|
|
|
|
18. TOTAL OUTSIDE LIABILITIES |
244.159 |
279.176 |
277.559 |
268.949 |
259.690 |
|
|
|
|
|
|
|
|
NETWORTH |
|
|
|
|
|
|
19
Share Capital |
50.000 |
50.000 |
50.000 |
50.000 |
50.000 |
|
|
|
|
|
|
|
|
20.
Share Application Money |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
21.
Subsidy from Govt. |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
22.
Loans from Family |
50.000 |
50.000 |
50.000 |
37.000 |
22.000 |
|
|
|
|
|
|
|
|
23.
Surplus or deficit in Profit & Loss account |
2.110 |
13.463 |
37.572 |
58.843 |
93.298 |
|
|
|
|
|
|
|
|
24. NET WORTH |
102.110 |
113.463 |
137.572 |
145.843 |
165.298 |
|
|
|
|
|
|
|
|
25. TOTAL LIABILITIES |
346.269 |
392.639 |
415.131 |
414.792 |
424.988 |
|
|
|
|
|
|
|
|
CURRENT ASSETS |
|
|
|
|
|
|
26.
Cash & bank balances |
2.491 |
2.531 |
4.450 |
3.538 |
3.366 |
|
|
|
|
|
|
|
|
27.
Investments (other than long term investments) |
|
|
|
|
|
|
i) Government and other trustee
securities/ CP, CD, MF |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
ii) Fixed deposits with Banks |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
28.
i) Receivables other than deferred and export receivables (including BP/BD,
but excluding BP/BD by banks drawn under LCs) |
51.954 |
96.311 |
135.231 |
149.278 |
165.066 |
|
ii) Export receivables (excluding bills purchased
and discounted by banks drawn under LCs) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
29.
Instalments of deferred receivables (due within one year) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
30. INVENTORY |
|
|
|
|
|
|
i) Raw materials |
|
|
|
|
|
|
a. Imported |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Indigenous |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
ii) Stocks in process |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
iii) Finished Goods |
29.848 |
74.918 |
84.044 |
94.232 |
105.477 |
|
|
|
|
|
|
|
|
iv) Other Consumable spares |
|
|
|
|
|
|
a. Imported |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Indigenous |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
31.
Advances to suppliers of raw materials, stores/ Loans & Advances |
8.912 |
3.704 |
3.924 |
4.166 |
5.933 |
|
|
|
|
|
|
|
|
32.
Advance payment of taxes |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
33.
Other current assets |
|
|
|
|
|
|
a. Margin on LCs/BGs- WC only |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Other CA assets |
4.439 |
4.883 |
6.348 |
6.665 |
6.998 |
|
|
|
|
|
|
|
|
34. TOTAL CURRENT ASSETS |
97.646 |
182.346 |
233.997 |
257.879 |
286.840 |
|
|
|
|
|
|
|
|
FIXED ASSETS |
|
|
|
|
|
|
35.
Opening Balance |
249.712 |
228.623 |
190.293 |
158.634 |
132.413 |
|
|
|
|
|
|
|
|
36.
Depreciation |
21.038 |
38.330 |
31.659 |
26.221 |
21.765 |
|
Work in Progress |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
37.
Closing Balance |
228.623 |
190.293 |
158.634 |
132.413 |
110.648 |
|
|
|
|
|
|
|
|
OTHER NON CURRENT ASSETS |
|
|
|
|
|
|
38.
Investments/ book debts/ advances/ deposits, which are not current assets |
|
|
|
|
|
|
i)
a. Investments - Others |
0.000 |
0.000 |
2.500 |
4.500 |
7.500 |
|
b. Others - Deposits |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
ii) Advances to suppliers of capital goods |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
iii) Deferred receivables |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
iv) Others/ICDs placed |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
39.
Non consumable stores |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
40.
Other non- current assets including dues from directors |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
41.TOTAL OTHER NON CURRENTS ASSETS |
0.000 |
0.000 |
2.500 |
4.500 |
7.500 |
|
|
|
|
|
|
|
|
42.
Intangible assets- Licence Purchase |
20.000 |
20.000 |
20.000 |
20.000 |
20.000 |
|
- |
|
|
|
|
|
|
43. TOTAL ASSETS |
346.269 |
392.639 |
415.131 |
414.792 |
424.988 |
|
- |
|
|
|
|
|
|
44.
Tangible Net Worth (TNW) |
82.110 |
93.463 |
117.572 |
125.843 |
145.298 |
|
45.
Net Working Capital (NWC) |
29.987 |
60.759 |
88.813 |
96.091 |
109.096 |
|
46.
Current Ratio (CR) |
1.44 |
1.50 |
1.61 |
1.59 |
1.61 |
|
47.
TOL / TNW Ratio |
2.97 |
2.99 |
2.36 |
2.14 |
1.79 |
|
|
|
|
|
|
|
|
ADDITIONAL INFORMATION |
|
|
|
|
|
|
i. ICDs placed |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
ii. ICDs taken |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
iii. Bk fin for bills under
LC |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
iv. Inv. in CP/CD/MF |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
v. Disputed indirect tax |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
vi. Others |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
Difference in balance sheet |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
------------------------------------------------------------------------------------------------------------------------------
FUND FLOW STATEMENT
(RS. IN MILLION)
|
PARTICULARS |
31.03.2017 |
31.03.2018 |
31.03.2019 |
31.03.2020 |
31.03.2021 |
|
|
|
|
|
|
|
|
1.
SOURCES |
|
|
|
|
|
|
a. Net Profit (after tax) |
11.353 |
24.109 |
36.771 |
49.455 |
66.246 |
|
|
|
|
|
|
|
|
b. Depreciation |
38.330 |
31.659 |
26.221 |
21.765 |
18.097 |
|
|
|
|
|
|
|
|
c. Increase in Capital |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
d. Increase in Term liabilities
(including public deposits) |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
e. Decrease in |
|
|
|
|
|
|
i)
Fixed Assets |
21.087 |
38.330 |
31.659 |
26.221 |
21.765 |
|
ii)
Other non-current assets |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
f. Decrease in Intangible |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL SOURCES OF FUNDS |
70.773 |
94.098 |
94.651 |
97.441 |
106.108 |
|
|
|
|
|
|
|
|
2.
USES OF FUNDS |
|
|
|
|
|
|
a. Net loss |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
b. Decrease in Term liabilities
(including public deposits) |
18.911 |
25.214 |
25.214 |
25.214 |
25.214 |
|
|
|
|
|
|
|
|
c. Increase in |
|
|
|
|
|
|
i)
Fixed Assets |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
ii)
Other non-current assets |
0.000 |
2.500 |
2.000 |
3.000 |
2.500 |
|
|
|
|
|
|
|
|
d. Dividend payments |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
e. Others |
|
|
|
|
|
|
ii) Incr. in Intangibles |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
2.
TOTAL USES OF FUNDS |
18.911 |
27.714 |
27.214 |
28.214 |
27.714 |
|
|
|
|
|
|
|
|
3. Long Term Surplus / Deficit (-) |
51.862 |
66.384 |
67.436 |
69.226 |
78.394 |
|
|
|
|
|
|
|
|
4. Increase/(-) decrease in Current Assets *
(as per details given below) |
84.701 |
51.651 |
23.882 |
28.960 |
50.314 |
|
|
|
|
|
|
|
|
5. Increase/(-) decrease in Current liabilities
other than bank borrowings |
43.928 |
13.598 |
6.604 |
5.955 |
7.685 |
|
|
|
|
|
|
|
|
6. Increase/(-)decrease in Working Capital gap |
40.773 |
38.054 |
17.278 |
23.005 |
42.629 |
|
|
|
|
|
|
|
|
7. Net Surplus /(-) Deficit |
11.089 |
28.330 |
50.159 |
46.221 |
35.765 |
|
|
|
|
|
|
|
|
8. Increase/(-)decrease in Bank borrowings |
10.000 |
10.000 |
10.000 |
10.000 |
10.000 |
|
|
|
|
|
|
|
|
INCREASE/(-)DECREASE IN SALES |
351.238 |
56.595 |
62.277 |
68.850 |
112.294 |
|
|
|
|
|
|
|
|
BREAKUP
OF ITEM NO(4) |
|
|
|
|
|
|
i) Increase/(-)decrease in raw materials |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
ii) Increase/(-)decrease in stocks in
process |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
iii) Increase/(-)decrease in Finished goods |
45.069 |
9.127 |
10.188 |
11.245 |
20.992 |
|
|
|
|
|
|
|
|
iv) Increase/(-)decrease in Receivables |
44.356 |
38.920 |
14.047 |
15.788 |
25.010 |
|
|
|
|
|
|
|
|
v) Increase/(-)decrease in stores &
spares |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
vi) Increase/(-)decrease in other current
assets |
(4.725) |
3.604 |
(0.352) |
1.928 |
4.312 |
|
|
|
|
|
|
|
|
TOTAL INCREASE/ (-) DECREASE |
84.701 |
51.651 |
23.882 |
28.960 |
50.314 |
------------------------------------------------------------------------------------------------------------------------------
COMPARATIVE STATEMENT OF CURRENT ASSETS
& CURRENT LIABILITIES
(RS. IN MILLION)
|
PARTICULARS |
31.03.2016 |
31.03.2017 |
31.03.2018 |
31.03.2019 |
31.03.2020 |
|
|
|
|
|
|
|
|
A. CURRENT ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
|
1.
Raw materials (including stores & other items used in the process of mfg) |
|
|
|
|
|
|
a. Imported: |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
(months of consumption) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
b. Indigenous |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
(months of consumption) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
2. Other Consumable spares (excluding those
included in 1. above |
|
|
|
|
|
|
a. Imported: |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
(months of consumption) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
b. Indigenous: |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
(months of consumption) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
3.
Stocks in process: |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
(months cost of production) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
4. Finished Goods |
9.848 |
74.918 |
84.044 |
94.232 |
105.477 |
|
(months cost of sales) |
1.97 |
1.83 |
1.90 |
2.00 |
2.08 |
|
|
|
|
|
|
|
|
5. Receivables other than deferred and export
receivables (incl. non-LC bills purchased and discounted by banks): |
51.954 |
96.311 |
135.231 |
149.278 |
165.066 |
|
(months
domestic sales excluding deferred payment sales) |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
6. Export receivables (incl. non-LC bills
purchased and discounted by banks): |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
Months export sales: |
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
7. Advance to suppliers |
8.912 |
3.704 |
3.924 |
4.166 |
5.933 |
|
|
|
|
|
|
|
|
8. Other current assets (Due within one year) |
6.930 |
7.414 |
10.798 |
10.203 |
10.364 |
|
|
|
|
|
|
|
|
9.
TOTAL CURRENT ASSETS |
97.646 |
182.346 |
233.997 |
257.879 |
286.840 |
|
|
|
|
|
|
|
|
B. CURRENT LIABILITIES |
|
|
|
|
|
|
(Other
than bank borrowings for working capital) |
|
|
|
|
|
|
|
|
|
|
|
|
|
10.
Creditors for purchase of raw materials, stores & consumable spares: |
12.518 |
32.649 |
31.658 |
32.863 |
35.631 |
|
Months purchases : |
0.82 |
0.82 |
0.79 |
0.76 |
0.76 |
|
|
|
|
|
|
|
|
11.
Advance from customers |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
12.
Statutory liabilities |
3.578 |
6.958 |
14.936 |
19.998 |
22.504 |
|
|
|
|
|
|
|
|
13.
Other current liabilities |
|
|
|
|
|
|
a. Short term borrowings |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
b. Dividend payable |
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
c. Deposits/ instalments of
TL/DPG/debentures etc |
0.000 |
18.911 |
25.214 |
25.214 |
25.214 |
|
d. others |
1.562 |
3.069 |
3.375 |
3.713 |
4.394 |
|
|
|
|
|
|
|
|
14.
TOTAL CURRENT LIABILITIES |
17.659 |
61.587 |
75.184 |
81.789 |
87.744 |
------------------------------------------------------------------------------------------------------------------------------
WORKING CAPITAL ASSESSMENT & ABF CALCULATION
(UNDER PBS METHOD)
(RS. IN MILLION)
|
PARTICULARS |
31.03.2016 |
31.03.2017 |
31.03.2018 |
31.03.2019 |
31.03.2020 |
|
|
|
|
|
|
|
|
1.
Total Current Assets (TCA) |
97.646 |
182.346 |
233.997 |
257.879 |
286.840 |
|
|
|
|
|
|
|
|
2.
Other Current Liabilities (OCL) (Other than Bank Borrowing) |
17.659 |
61.587 |
75.184 |
81.789 |
87.744 |
|
|
|
|
|
|
|
|
3.
Working Capital Gap(WCG) |
79.987 |
120.759 |
158.813 |
176.091 |
199.096 |
|
|
|
|
|
|
|
|
4.
Net Working Capital (Actual/Projected) |
29.987 |
60.759 |
88.813 |
96.091 |
109.096 |
|
|
|
|
|
|
|
|
5.
Assessed Bank Finance (ABF) |
50.000 |
60.000 |
70.000 |
80.000 |
90.000 |
|
|
|
|
|
|
|
|
6.
NWC to TCA (%) |
30.71 |
33.32 |
37.95 |
37.26 |
38.03 |
|
|
|
|
|
|
|
|
7.
Bank Finance to TCA (%) |
61.45 |
38.39 |
34.19 |
34.90 |
34.86 |
|
|
|
|
|
|
|
|
8.
Sundry Creditors to TCA (%) |
12.82 |
17.91 |
13.53 |
12.74 |
12.42 |
|
|
|
|
|
|
|
|
9.
Other CL to TCA (%) |
5.26 |
15.87 |
18.60 |
18.97 |
18.17 |
|
|
|
|
|
|
|
|
10.
Inventories to Net Sales (days) |
52 |
49 |
50 |
51 |
51 |
|
|
|
|
|
|
|
|
11.
Receivables to Gross Sales (days) |
90 |
63 |
80 |
80 |
80 |
|
|
|
|
|
|
|
|
12.
Sundry Creditors to Purchases (days) |
25 |
25 |
24 |
23 |
23 |
------------------------------------------------------------------------------------------------------------------------------
FINANCIAL INDICATORS
(RS. IN MILLION)
|
PARTICULARS |
31.03.2016 |
31.03.2017 |
31.03.2018 |
31.03.2019 |
31.03.2020 |
|
|
|
|
|
|
|
|
a.
PBDIT |
45.272 |
89.567 |
98.789 |
109.097 |
120.607 |
|
|
|
|
|
|
|
|
b.
Net Profit / Sales (in %) |
1.00 |
2.02 |
3.90 |
5.40 |
6.60 |
|
|
|
|
|
|
|
|
c.
Net Profit / Total Funds (in %) |
0.61 |
2.89 |
5.81 |
8.86 |
11.64 |
|
|
|
|
|
|
|
|
d.
Cash Accruals |
23.147 |
49.683 |
55.768 |
62.992 |
71.220 |
|
|
|
|
|
|
|
|
e.
Retained Accruals |
23.147 |
49.683 |
55.768 |
62.992 |
71.220 |
|
|
|
|
|
|
|
|
f.
Retained Accrual/Cash Accrual (in %) |
100.00 |
100.00 |
100.00 |
100.00 |
100.00 |
|
|
|
|
|
|
|
|
g.
PBDIT / Net Sales (in %) |
21.49 |
15.94 |
15.97 |
16.02 |
16.09 |
|
|
|
|
|
|
|
|
h.
PBDI / Interest (Times) |
2.25 |
2.66 |
2.99 |
3.41 |
3.95 |
|
|
|
|
|
|
|
|
i.
ROCE |
1.388 |
2.404 |
2.500 |
2.763 |
2.978 |
|
|
|
|
|
|
|
|
j.
INV + REC / Net Sales (Days) |
157.15 |
113.62 |
131.71 |
132.78 |
134.61 |
------------------------------------------------------------------------------------------------------------------------------
COLLATERAL SECURITIES
(RS. IN MILLION)
|
LIST OF PROPERTY
TO BE OFFERED AS A CROSS COLLATERAL |
AMOUNT |
|
|
|
|
Residential Flat located at Flat No. 307, B
Wing Ekta Bhoomi Garden III, Dattapada Road, Borivali (East), Mumbai 66 owned
by Mr. Vinod Dali area measuring 1050 Sq. ft. |
15.000 |
|
|
|
|
Commercial Property located at Shop No. 6,
Ground Floor, Praythmesh Hill, Kolset Road, Thane (West) owned by Mr. Sanjeev
Gupta area measuring 325 Sq. ft. |
12.500 |
|
|
|
|
Commercial Property located at Office No.
211, 2nd Floor, E Square, Subhase Road, Vile Parle (East), Mumbai
– 400057 owned by Mr. Rajesh Ghangurde (HUF) area admeasuring 334 Sq. ft. |
20.000 |
|
|
|
|
Residential property located at 407/B, Satyam
CHS Limited, New Link Road, Opposite MHB Post Office, Borivali (West), Mumbai
– 400091 area admeasuring 550 Sq. ft. |
9.500 |
|
|
|
|
Land located at Survey No. 398/3 area H-R-P,
0-50-0 and Survey No. 398/6 area H-R-P, 0-78-0 total area H-R-P, 1-28-0 and
Survey No. 398/8/1 area H-R-P, 0-40-0 and Survey No. 398/8/2 area H-R-P,
0-79-0 and Survey No. 398/8/1 area H-R-P, 0-40-0 and Survey No. 405/2P/B area
H-R-P, 1-0-0and Survey No. 404/6P area H-R-P, 1-60-0 and Survey No. 405/1P
area H-R-P, 1-20-0 and Survey No. 398/2P area H-R-P, 0-40-0 and Survey No.
404/4 area H-R-P, 1-09-0 and Survey No. 405/1P area H-R-P, 0-25-0 and Survey
No. 404/5P area H-R-P, 2-80-0 and Survey No. 404/6P area H-R-P, 0-80-0 mauje
Kharade, Sahapur, Thane owned by Mr. Hitesh Asrani |
100.000 |
|
|
|
|
Total |
157.000 |
------------------------------------------------------------------------------------------------------------------------------
NETWORTH STATEMENT
MR. VINOD ANANT DALI
(RS. IN MILLION)
|
PARTICULARS
|
31.03.2015 |
|
|
ASSETS |
|
|
|
Share Investment |
|
0.022 |
|
Spiro Lifecare Private Limited [2250 Shares
of Rs. 10/-] |
0.022 |
|
|
|
|
|
|
Other Investment |
|
17.600 |
|
Residential Property at Borivali (Kusum
Bharti) 50% |
6.750 |
|
|
Residential Property at Borivali (Ekta
Bhoomi) – 600 Sq. ft. 50% |
8.750 |
|
|
Securities and Other Investment |
2.100 |
|
|
|
|
|
|
Current Assets |
|
10.646 |
|
Cash and Bank Balance |
0.153 |
|
|
Gold at Market Value |
2.056 |
|
|
Loans and Advances |
8.437 |
|
|
|
|
|
|
Reserves and Surplus (Upto March 2014) |
|
(0.033) |
|
25% in Spiro Lifecare Private Limited |
(0.033) |
|
|
|
|
|
|
LIABILITIES |
|
0.000 |
|
|
|
|
|
TOTAL |
|
28.235 |
------------------------------------------------------------------------------------------------------------------------------
NETWORTH STATEMENT
MR. RAJESH SHRIPAD GHANGURDE
(RS. IN MILLION)
|
PARTICULARS
|
31.03.2015 |
|
|
ASSETS |
|
|
|
Share Investment |
|
0.150 |
|
Apple Lifecare (India) Private Limited [2500
Shares of Rs. 10/-] |
0.025 |
|
|
Ozean Futura Private Limited [10000 Shares
of Rs. 10/-] |
0.100 |
|
|
Spiro Lifecare Private Limited [2250 Shares
of Rs. 10/-] |
0.025 |
|
|
|
|
|
|
Other Investment |
|
13.211 |
|
Residential Property at Lavasa 3000 Sq. ft.
50% |
10.000 |
|
|
Securities and Other Investment |
3.211 |
|
|
|
|
|
|
Current Assets |
|
11.206 |
|
Cash and Bank Balance |
0.756 |
|
|
Loans and Advances |
9.512 |
|
|
Gold at Market Value |
0.938 |
|
|
|
|
|
|
Reserves and Surplus (Upto March 2014) |
|
0.728 |
|
12.5% in Desano Pharmaceuticals (India)
Private Limited |
2.889 |
|
|
50% in Ozean Futura Private Limited |
(2.157) |
|
|
25% in Spiro Lifecare Private Limited |
(0.004) |
|
|
|
|
|
|
LIABILITIES |
|
0.000 |
|
|
|
|
|
TOTAL |
|
25.295 |
------------------------------------------------------------------------------------------------------------------------------
NETWORTH STATEMENT
MR. SANJEEV ANANT GUPTE
(RS. IN MILLION)
|
PARTICULARS
|
31.03.2015 |
|
|
ASSETS |
|
|
|
Investment |
|
30.104 |
|
Residential Property at Sumer Castle (Market
Value) |
12.500 |
|
|
Commercial Property at Prathmesh Hills (Market
Value) |
12.500 |
|
|
Securities and Other Investment |
5.104 |
|
|
|
|
|
|
Current Assets |
|
11.812 |
|
Cash and Bank Balance |
1.018 |
|
|
Gold at Market Value |
1.046 |
|
|
Loans and Advances |
9.748 |
|
|
|
|
|
|
LIABILITIES |
|
0.000 |
|
|
|
|
|
TOTAL |
|
41.916 |
------------------------------------------------------------------------------------------------------------------------------
NETWORTH STATEMENT
MR. PANKAJ RAMESHCHANDRA VYAS
(RS. IN MILLION)
|
PARTICULARS
|
31.03.2015 |
|
|
ASSETS |
|
|
|
Share Investment |
|
1.566 |
|
Investment in Mutual Fund |
0.050 |
|
|
Shares |
1.516 |
|
|
|
|
|
|
Other Investment |
|
8.250 |
|
Residential Property at Borivali (50%)
Market Value |
4.750 |
|
|
Residential Property at Bhayander Market
Value |
3.500 |
|
|
|
|
|
|
Current Assets |
|
8.096 |
|
Cash and Bank Balance |
0.846 |
|
|
Gold at Market Value |
0.400 |
|
|
LIC of India |
0.900 |
|
|
Loans and Advances |
5.950 |
|
|
|
|
|
|
LIABILITIES |
|
0.750 |
|
ICICI Housing Loan |
0.750 |
|
|
|
|
|
|
TOTAL |
|
17.162 |
------------------------------------------------------------------------------------------------------------------------------
NETWORTH STATEMENT
MR. HITESH PARMANAND ASRANI
(RS. IN MILLION)
|
PARTICULARS
|
31.03.2015 |
|
|
ASSETS |
|
|
|
Share Investment |
|
56.310 |
|
CRP Technology (India) Private Limited
[5601020 Shares of Rs. 10/-] |
56.010 |
|
|
Axis Resources Private Limited [1 Share of
Rs. 10/-] |
0.000 |
|
|
Apple Lifecare (India) Private Limited [2500
Shares of Rs. 10/-] |
0.025 |
|
|
Mediline Pharmaceuticals (India) Private
Limited [9990 Shares of Rs. 10/-] |
0.100 |
|
|
Ginger Country Living Private Limited [5000
Shares of Rs. 10/-] |
0.050 |
|
|
Ozean Futura Private Limited [10000 Shares
of Rs. 10/-] |
0.100 |
|
|
Spiro Lifecare Private Limited [2250 Shares
of Rs. 10/-] |
0.025 |
|
|
|
|
|
|
Other Investment |
|
112.500 |
|
HDFC AMP |
0.500 |
|
|
Land (Market Value) |
112.000 |
|
|
|
|
|
|
Current Assets |
|
16.957 |
|
Cash and Bank Balance |
0.891 |
|
|
Loans and Advances |
15.052 |
|
|
Gold at Market Value |
1.014 |
|
|
|
|
|
|
Reserves and Surplus (Upto March 2014) |
|
120.175 |
|
80.16% in CRP Technology (India) Private
Limited |
118.731 |
|
|
0.01% in Axis Resources Private Limited |
0.029 |
|
|
12.5% in Desano Pharmaceuticals (India)
Private Limited |
2.889 |
|
|
99.9% in Mediline Pharmaceuticals (India)
Private Limited |
0.697 |
|
|
50% in Ginger Country Living Private Limited |
(0.010) |
|
|
50% in Ozean Futura Private Limited |
(2.157) |
|
|
25% in Spiro Lifecare Private Limited |
(0.004) |
|
|
|
|
|
|
LIABILITIES |
|
|
|
Loans taken |
|
0.204 |
|
From Financial Institution |
0.204 |
|
|
|
|
|
|
TOTAL |
|
305.738 |
------------------------------------------------------------------------------------------------------------------------------
PROJECT REPORT
MARKET EXPERTISE
Their promoter and managing
director, Mr. Sanjeev Gupte, was heading the International sales for Cipla for
the last 25 years. He was instrumental in achieving and managing a sales
portfolio of over INR 50000.000 Million nearly USD 1 Billion per annum. Under
him, they have created the best in the industry Business development team with
a wealth of experience. This, along with active relationships with leading
distributors and large customers across 180 countries in the world places them
in a unique position to achieve unprecedented growth.
SOURCING EXPERTISE
Their other promoting
director, Mr. Rajesh Ghangurde, was heading the global procurement at Cipla
handling sourcing to the tune of INR 35000.000 Million per year [nearly USD 600
million]. Using his specialised expertise, they have identified reputed
manufacturers, having the necessary regulatory approvals, which are having a
large quantum of unutilised capacities. They have already entered into long
term contracts with a few wherein they are underwriting a portion of their
manufacturing capacity and having a first right of refusal in the same.
Together, these factors
lead to a business model which is not very capital intensive and yet has all
the advantages and controls that a pharmaceutical manufacturing setup might
aspire for.
FINANCIAL MODEL
Their target therapeutic areas
include both the human healthcare as well as the veterinary product lines.
Within this, they have received clear product indications from their customers
for which they are now aggressively investing their energies on the sourcing.
The financial numbers that
are presented in this business report are directly derived from these actual
product universe shared with them by their customers. They have given clear
mandates to source these, along with the annual projected quantities and
indicative rates.
They have gone ahead in
their quest to arrive at a deep-water scenario and discounted this demand by
phasing out the product registrations across a longer period and restricting
sales to realistic conversion percentages for the bulk of the product line.
COST OF PROJECT
AND MEANS OF FINANCE
|
Cost of Project |
Amount |
Means of Finance |
Amount |
|
|
|
||
|
Fixed Assets |
2.495 |
Prompter's Contribution |
0.500 |
|
|
|||
|
Unsecured Loan |
|||
|
From Family members |
0.230 |
||
|
|
|||
|
Term Loan |
1.765 |
||
|
|
|
||
|
Total |
2.495 |
Total |
2.495 |
SPIRO IDEOLOGY
STRATEGY
The generic life cycle of a product is
getting shortened. Going ahead, they are anticipating that companies will need to
be leaner and focus on achieving a competitive edge in the market.
The Spiro model is a dynamic answer to this
threat. They look at this as a challenging opportunity, where they can
demonstrate the value of their fully backward integrated supply chain to their
in-depth, end to end knowledge of their target therapeutic segments including
sourcing, technology and regulatory compliance. This rests on a strong platform
of their strategic partnerships with leading manufacturers of speciality
products. Coupled with the strength of their robust global business development
platform, this gives them a distinct ability to reach out to over 150 countries
simultaneously forming the substratum of the Spiro strategy.
VISION
Their vision is to develop a strong specialized pipeline and form
innovative collaborations. This will enable their customers to have the fastest
access to the newest products. They are a knowledge based marketing and
business development organization that continues to bring a progressive approach
and energy to the product identification, development and market integration
process with the belief that what they do affects lives positively.
MISSION
To be the partner of first choice across their target geographies for
their customers who rely on their knowledge based approach for sustaining and
expanding their product portfolio keeping innovation, competitiveness and
quality as their benchmarks.
PHARMACEUTICAL INDUSTRY OVERVIEW
The Indian Pharmaceutical Industry
is expected to witness robust growth
·
The
Indian Pharmaceutical Industry revenues stood at USD 32bn in FY13. It is
expected to grow at a CAGR of 14% to reach USD 61bn by FY18E.
·
Exports
form an important constituent of the industry, contributing to ~45% of the
formulations segment and 80-90% of the intermediates and API segment
·
The
revenue split of India’s pharmaceutical industry by segment is depicted below :
·
The
domestic formulations market was valued at USD 11.7bn in FY13 and is expected
to grow at a 13% CAGR, driven by greater purchasing power in India, and an
increase in prevalence of chronic, lifestyle diseases in India.
·
The
export formulations market is expected to grow at a CAGR of 15%, buoyed by a
growing opportunity from drugs going off-patent in the regulated markets and a
favourable growth in the semi-regulated markets.
·
Bulk
drug exports, constituting, 80-90% of total bulk drugs production, are expected
to grow at a CAGR of 13%, given the conducive macro-environment and India
gaining prominence as an outsourcing destination.
· In terms of revenue, the Asthma and COPD therapeutic area historically ranks sixth largest single source of sales for the pharmaceutical industry.
·
The outlook of the market is currently strong
driven by strategically sound lifecycle management from the major players in
asthma and COPD.
COMPANY OVERVIEW
BEST ON CLASS
PROMOTERS TEAM
Sanjeev Gupte,
Managing Director
Sanjeev was heading the International sales for one of India’s largest generic
company for the last 25 years managing over 6000 crores of annual sales across
the global markets. He has his academic background in the science stream and
had done his Management studies from the prestigious Jamnalal Bajaj Institute
of Management studies. He had under him over 500 people globally in his last
employ. Sanjeev is very passionate about taking Spiro to similar great heights
and beyond.
Rajesh Ghangurde,
Director
Rajesh was responsible for the global supply chain having a sourcing
portfolio of over INR 3,500 crores under his charge along with additional
responsibility to manage the government liason machinery. Apart from this, he
was single handedly responsible to take the Australia and New Zealand market to
over USD 50 Million while he was managing the exports to these markets in
parallel. His domain expertise has been honed over the last 20 years in the
pharma industry. Rajesh brings with him priceless global relationships from his
procurement days to Spiro which is going to be a large factor in giving them
the competitive edge.
Vinod Dali,
Director
With a bachelors degree in Pharmacy, Vinod is equipped to handle both the technical as well as the commercial
aspects of business. He started his career in Cipla in the formulation production
team
where he was also involved in the production planning and regulatory domains.
Later he went on to join the Export department. Vinod headed the business
development team managing the entire Latin America and Iran with a portfolio of
over 400 crores for over 18 years. These are some of Spiro’s key market.
Hitesh Asrani,
Director
Hitesh has over 10 years of API business experience managing the Indian
operation of one of the largest Chinese Anti Aids [ARVs] company with sales of
over 1000 crores through the Indian market. He has his credentials in commerce
and has done his management studies from K C College with a specialization in
Marketing. He has behind him a vast experience in managing large teams and is
specializing in corporate strategy and scale up planning.
Pankaj Vyas,
Director
Pankaj is a certified chartered accountant. With an experience of over
22 years in financial planning and execution, he brings the prudence and
reliability in Spiro’s financial dealings.
PRODUCTION
BRIEF DESCRIPTION OF PRODUCTION OPERATIONS:
The active ingredients and excipients for batch manufacturing are
dispensed batch wise and all the relevant details, such as weight, batch
number, analytical reference number etc. are verified. Before commencing
production activities, area clearance is certified by QA. The manufacturing
environment is maintained at the required levels of temperature, humidity and
cleanliness.
Unit operations are carried out in dedicated areas like, dispensing, sifting,
blending, homogenisation, mixing and filling in the desired primary packaging
material.
In-process checks are carried out through out production and packing
process as per batch manufacturing and packing. The content of all the vessels
and containers used in manufacture and storage during the various manufacturing
stages are conspicuously labelled with the name of the product, batch number,
batch size and stage of manufacturing to prevent any cross contamination and
mix-ups.
Further processing is done only after the in-process results are
obtained from Quality Control / in-process QA.
Semi-finished products are transferred to packing on preliminary
approval from Quality Assurance Department.
After packing, finished products are transferred to finished goods store
area and dispatched for distribution / sale after approval by QA.
ARRANGEMENTS FOR HANDLING OF STARTING MATERIAL, BULK AND FINISHED
PRODUCTS:
Warehouse has been designed to allow orderly arrangement of various categories
of materials and products like starting and packing materials, intermediates,
bulk and finished products, products in quarantine, released, rejected,
returned or recalled products. Segregation is provided for the storage of
rejected, recalled or returned materials or products. Such area, material or
product is suitably marked and secured. Access to these areas and materials is
restricted.
Adequate fire protection measures are adopted by placing fire
extinguishers at suitable points.
Proper racks, bins and platforms are provided for the storage of
materials. Sampling of Active ingredients and excipients is done in a separate
room under reverse laminar air flow booth.
The received material is dedusted in receiving bay and then placed in
quarantine area.
All the materials upon receipt, are inspected, sampled and tested
according to the test procedures and specifications.
Authorised person affixes the label to indicate various stages of the
materials under test differentiated by colour code behind the test for easy
identification of the status.
· Yellow – Material under Test
· Green – Approved Material
· Red –Rejected material
The rejected material, if any, is moved to the area marked for its
storage.
Material that meets All Quality Control Specifications are approved for
production or packing.
First In – First Expiry and First Out is followed for dispensing of all
the materials from the stores. Deviation, if any, from the system is
documented.
Damaged containers, if any, are identified, recorded, segregated and
informed to vendor / supplier accordingly.
Intermediate and finished products are held under quarantine. They are
samples and tested according to the written procedures, specifications and test
methods. These are approved for packing if all the quality control tests
complies with the specifications criteria.
Record of manufacturing parameters and in-process checks are kept along
with the batch Manufacturing and packing. Production data is entered by
production staff, results of in-process checks, is entered in each BMR / BPR
and the quality control reports are attached. All completed batch records are
reviewed by Quality Assurance Department before releasing the batch.
Finished products are approved for packing and final batch release is
given by the in charge QA or designee.
Arrangement for reprocessing or rework:
There is no standard operating procedure for reprocessing or rework.
Arrangements for handling of Rejected Materials and Products
All rejected raw and packaging materials are labelled as ‘REJECTED” and
kept in a respective reject areas.
The rejected raw material / unprinted packaging material is either sent
back to the supplier or destroyed. Printed packaging material is destroyed in
the premises after information to the supplier or printer.
Rejected Intermediates, finished products and returned products shall be
investigated and verified as per SOP by QC / QA to find out of the causes of
rejection.
General Policy for Process Validation:
Process Validation is carried out according to approved validation
protocol. The protocol defines the critical variables to be assessed at each
stage in the process together with the acceptance criterion to be met. Process
validation carried out on for three consecutive batches as per Validation
master Plan.
GLOBAL DISTRIBUTION NETWORK
The Spiro network is broken up into six
distinct regions:
Together these six regions cover the geography
where they have established their reach. Every regions is driven by a dedicated
team of expert professionals who have the grass root understanding of their
target markets, including the regulatory landscape, patents, distribution
structures and cultural diversity.
Spiro is a consolidation of multiple
strategies, which are best suited for every region, integrated together into
their broad goals to create optimum value for their customers and manufacturing
partners.
----------------------------------------------------------------------------------------------------------------------------
INDEX OF CHARGES: NO
CHARGES EXIST FOR COMPANY
----------------------------------------------------------------------------------------------------------------------------
TRADE REFERENCES
· Pandit Archengers
Contact Person: Mr. Amit Pandit
[91-9820290749]
· Punarnava Construction and Infrastructure Private Limited
Contact Person: Mr. Lobo
[91-9820121957]
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-trrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or investigation
registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No available
information exist that suggest that subject or any of its principals have been
formally charged or convicted by a competent governmental authority for any
financial crime or under any formal investigation by a competent government
authority for any violation of anti-corruption laws or international anti-money
laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. 63.88 |
|
|
1 |
Rs. 98.47 |
|
Euro |
1 |
Rs. 72.15 |
INFORMATION DETAILS
|
Information
Gathered by : |
PPT |
|
|
|
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
BVA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.